Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, June 14, 2024 | Back issues
Courthouse News Service Courthouse News Service

Pharma Merger

Directors are selling CoLucid Pharmaceuticals too cheaply through an unfair process to Eli Lilly, for $46.50 a share or $897 million, shareholders say in a federal class action.

BOSTON – Directors are selling CoLucid Pharmaceuticals too cheaply through an unfair process to Eli Lilly, for $46.50 a share or $897 million, shareholders say in a federal class action.

Categories / Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...